Quest Diagnostics (DGX) Announces Organizational Changes

Go back to Quest Diagnostics (DGX) Announces Organizational Changes

CFRA Downgrades Quest Diagnostics (DGX) to Hold

April 21, 2022 1:53 PM EDT

CFRA downgraded Quest Diagnostics (NYSE: DGX) from Buy to Hold with a price target of $157.00 (from $160.00).

For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.

Shares of Quest Diagnostics closed at $138.45 yesterday.

... More